A case of hepatocellular carcinoma with liver cirrhosis type C surviving over 2 years by repeated transarterial infusion therapy using cisplatinum

A 58-year-old man with hepatocellular carcinoma (HCC) with liver cirrhosis type C was admitted to our division in April, 2004 to receive transarterial chemo-embolization (TACE) as a first-line chemotherapy for HCC. Thereafter, he had TACE twice for multicentric HCC. In December, 2005, TACE was thoug...

Full description

Saved in:
Bibliographic Details
Published inGan to kagaku ryoho Vol. 36; no. 8; p. 1347
Main Authors Miura, Tomofumi, Tsuboi, Yasunori, Takano, Toru, Ozeki, Yutaka, Nakamura, Junichiro, Yamada, Satoshi, Miura, Tsutomu, Yanagi, Masahiko, Takahashi, Toru
Format Journal Article
LanguageJapanese
Published Japan 01.08.2009
Subjects
Carcinoma, Hepatocellular - complications
Carcinoma, Hepatocellular - drug therapy
Cisplatin - administration & dosage
Hepatitis C, Chronic - complications
Humans
Infusions, Intra-Arterial
Liver Cirrhosis - complications
Liver Neoplasms - complications
Liver Neoplasms - drug therapy
Male
Middle Aged
Online AccessGet more information

Cover

More Information
Summary:A 58-year-old man with hepatocellular carcinoma (HCC) with liver cirrhosis type C was admitted to our division in April, 2004 to receive transarterial chemo-embolization (TACE) as a first-line chemotherapy for HCC. Thereafter, he had TACE twice for multicentric HCC. In December, 2005, TACE was thought to have become ineffective since his multicentric HCC progressed. So, we employed transarterial injection therapy (TAI) with fine powder cisplatinum (IAC) as a second-line chemotherapy. Stable disease was accomplished by the 22 sessions of TAI with IAC. After February 2008, IAC was given in combination with degradable starch microspheres (DSM) to reinforce the anti-cancer effect. The total therapeutic sessions using IAC became 26 in number. Total IAC amount used reached to more than 2,200 mg without any serious adverse reaction. In conclusion, TAI using IAC is thought to be effective in the chemotherapy of HCC, safely controlling the tumor progression.
ISSN:0385-0684